JPM23: Bayer hikes sales targets for Kerendia, Nubeqa to $3B each

For Bayer's splashy reveal at the J.P. Morgan Healthcare Conference, the drugmaker raised its peak sales projection for its heart medication Kerendia and prostate cancer treatment Nubeqa to 3 billion euros ($3.2 billion) each.